B cells are the antibody-producing arm of the adaptive immune system and play a critical role in controlling pathogens. Several groups have now demonstrated the feasibility of using engineered B cells as a therapy, including infectious disease control and gene therapy of serum deficiencies. These studies have largely utilized ex vivo modification of the cells. Direct in vivo engineering would be of utility to the field, particularly in infectious disease control where the infrastructure needs of ex vivo cell modification would make a broad vaccination campaign highly challenging. In this study we demonstrate that engineered adenoviral vectors are capable of efficiently transducing murine and human primary B cells both ex vivo and in vivo. We found that unmodified human adenovirus C5 was capable of infecting B cells in vivo, likely due to interactions between the virus penton base protein and integrins. We further describe vector modification with B cell-specific gene promoters and successfully restrict transgene expression to B cells, resulting in a strong reduction in gene expression from the liver, the main site of human adenovirus C5 infection in vivo.

Original languageEnglish
Pages (from-to)2600-2611
Number of pages12
JournalMolecular Therapy
Issue number9
StatePublished - Sep 6 2023


  • B cells
  • B lymphocytes
  • adenovirus
  • gene delivery
  • targeting
  • vectors


Dive into the research topics of 'Adenoviral vectors infect B lymphocytes in vivo'. Together they form a unique fingerprint.

Cite this